Jupiter Asset Management Ltd. increased its stake in Kura Oncology, Inc. (NASDAQ:KURA – Free Report) by 234.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 57,877 shares of the company’s stock after purchasing an additional 40,560 shares during the quarter. Jupiter Asset Management Ltd. owned approximately 0.08% of Kura Oncology worth $528,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also recently bought and sold shares of KURA. Franklin Resources Inc. grew its stake in Kura Oncology by 2.8% during the 2nd quarter. Franklin Resources Inc. now owns 1,224,497 shares of the company’s stock valued at $12,955,000 after acquiring an additional 32,821 shares in the last quarter. Bank of New York Mellon Corp grew its position in Kura Oncology by 10.9% during the third quarter. Bank of New York Mellon Corp now owns 261,744 shares of the company’s stock valued at $2,387,000 after purchasing an additional 25,677 shares in the last quarter. Suvretta Capital Management LLC increased its stake in Kura Oncology by 6.9% in the 2nd quarter. Suvretta Capital Management LLC now owns 7,028,442 shares of the company’s stock valued at $74,361,000 after buying an additional 455,107 shares during the period. Hennion & Walsh Asset Management Inc. increased its stake in Kura Oncology by 4.1% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 50,700 shares of the company’s stock valued at $462,000 after buying an additional 2,013 shares during the period. Finally, Prosight Management LP purchased a new stake in Kura Oncology in the 2nd quarter worth approximately $14,213,000.
Insider Transactions at Kura Oncology
In other news, SVP Thomas James Doyle sold 2,318 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $17.80, for a total transaction of $41,260.40. Following the completion of the transaction, the senior vice president now directly owns 48,093 shares in the company, valued at $856,055.40. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, COO Kathleen Ford sold 1,496 shares of the company’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $17.80, for a total transaction of $26,628.80. Following the completion of the transaction, the chief operating officer now owns 21,602 shares of the company’s stock, valued at $384,515.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Thomas James Doyle sold 2,318 shares of the stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $17.80, for a total transaction of $41,260.40. Following the completion of the sale, the senior vice president now owns 48,093 shares of the company’s stock, valued at approximately $856,055.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 96,919 shares of company stock worth $1,946,415. Company insiders own 5.60% of the company’s stock.
Kura Oncology Trading Down 1.8 %
Wall Street Analyst Weigh In
Several research firms have recently commented on KURA. HC Wainwright restated a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a report on Friday, December 8th. Mizuho started coverage on Kura Oncology in a research note on Friday, December 22nd. They set a “buy” rating and a $26.00 price target for the company. StockNews.com upgraded Kura Oncology from a “sell” rating to a “hold” rating in a report on Thursday, February 1st. JMP Securities increased their price objective on Kura Oncology from $22.00 to $32.00 and gave the stock a “market outperform” rating in a report on Wednesday, January 31st. Finally, Wedbush cut their price objective on shares of Kura Oncology from $40.00 to $37.00 and set an “outperform” rating on the stock in a research report on Friday, November 3rd. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $28.28.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications.
- Five stocks we like better than Kura Oncology
- What is the Nikkei 225 index?
- Uber quadruples EPS estimates, but is growth decelerating?
- With Risk Tolerance, One Size Does Not Fit All
- 3 stocks set to benefit from record Valentine’s Day spending
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Tradeweb is a disruptive pure play on financial market liquidity
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.